Dimensional Fund Advisors LP Buys 171,046 Shares of STAAR Surgical (NASDAQ:STAA)

Dimensional Fund Advisors LP boosted its holdings in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 25.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 853,370 shares of the medical instruments supplier's stock after acquiring an additional 171,046 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.73% of STAAR Surgical worth $20,728,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in STAA. JPMorgan Chase & Co. raised its stake in shares of STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier's stock valued at $7,978,000 after acquiring an additional 172,779 shares in the last quarter. Defender Capital LLC. raised its position in shares of STAAR Surgical by 3.5% in the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier's stock valued at $17,041,000 after purchasing an additional 23,950 shares during the period. KBC Group NV lifted its stake in shares of STAAR Surgical by 5,700.9% in the fourth quarter. KBC Group NV now owns 96,585 shares of the medical instruments supplier's stock worth $2,346,000 after buying an additional 94,920 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of STAAR Surgical during the 4th quarter worth $923,000. Finally, Barclays PLC grew its stake in STAAR Surgical by 349.4% in the 3rd quarter. Barclays PLC now owns 91,707 shares of the medical instruments supplier's stock valued at $3,406,000 after buying an additional 71,301 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock traded down $0.17 during trading on Friday, hitting $19.36. 970,771 shares of the company's stock traded hands, compared to its average volume of 808,612. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $49.86. The company has a market cap of $958.82 million, a PE ratio of -47.22 and a beta of 0.65. The firm's fifty day moving average price is $17.57 and its 200 day moving average price is $21.92.

Insider Buying and Selling at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. purchased 497,631 shares of the business's stock in a transaction dated Friday, April 4th. The shares were acquired at an average price of $15.91 per share, with a total value of $7,917,309.21. Following the completion of the purchase, the insider now directly owns 13,194,210 shares of the company's stock, valued at $209,919,881.10. The trade was a 3.92 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have purchased 1,742,581 shares of company stock valued at $28,407,543. 1.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on STAA shares. StockNews.com lowered shares of STAAR Surgical from a "hold" rating to a "sell" rating in a research report on Thursday, February 13th. Mizuho lowered STAAR Surgical from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $45.00 to $17.00 in a report on Wednesday, February 12th. Wells Fargo & Company started coverage on STAAR Surgical in a report on Monday, April 21st. They set an "equal weight" rating and a $17.00 price target for the company. Canaccord Genuity Group boosted their target price on shares of STAAR Surgical from $17.00 to $20.00 and gave the stock a "hold" rating in a research report on Thursday. Finally, Stifel Nicolaus cut their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $24.63.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.